Back

Safety and effectiveness of the use of ivabradine in patients with HFrEF heart failure and renal replacement therapy with hemodialysis

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pathophysiology and mechanisms 6 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rafael Rascon Sabido

Mexican Institute of Social Security (IMSS), Veracruz (Mexico)

7 More presentations in this session

Presentation thumbnail
Divergent clinical trajectories in heart failure: clinical profiles and outcomes in reduced versus preserved ejection fraction patients
Doctor J. Hurtado Cordova (Tlalpan, MX)
Abstract Slides Video
Presentation thumbnail
Unlocking SGLT2 inhibitors: evaluating elderly HFrEF patients with and without T2DM
Mrs H. Ismail (Kuala Lumpur, MY)
Abstract Slides Video
Presentation thumbnail
Endothelial dysfunction and hospitalization risk in heart failure with reduced ejection fraction: insights from microvascular reactivity assessment
Doctor S. Charfeddine (Sfax, TN)
Abstract Slides
Presentation thumbnail
Links between abnormal exercise parameters and diastolic dysfunction in heart failure with reduced ejection fraction
Doctor A. Attanasio (San Donato Milanese, IT)
Abstract Slides Video
Presentation thumbnail
Echocardiographic characteristics of patients with CpcPH, and IpcPH in HFrEF, Insight of PHHF study. Insight of PHHF study
Doctor E. Berthelot (Le Kremlin-Bicetre, FR)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pathophysiology and mechanisms 6

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Safety and effect of EMPAGLIFOZIN in patients with HF reduced LVEF in renal function replacement therapy. Adjustments needed for real life
thumbnail
Congress Presentation
Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.
thumbnail
Congress Presentation
Safety and use de trimetazidine in Cancer Therapy-Related Cardiac Dysfunction (CTRCD) secondary to breast cancer for LVEF recovery.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources